<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796066</url>
  </required_header>
  <id_info>
    <org_study_id>TSN2898-201</org_study_id>
    <nct_id>NCT02796066</nct_id>
  </id_info>
  <brief_title>TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of TSN2898 Topical Gel for the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thesan Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thesan Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of TSN 2898 topical
      gel in the treatment of moderate to severe acne.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TSN2898 is an inhibitor of stearoyl-CoA desaturase-1 (SCD-1), an enzyme present in sebaceous
      glands and a key regulatory enzyme in lipogenesis. This study will assess the safety and
      efficacy of TSN2898 topical gel and matched gel vehicle, applied daily on the face for the
      treatment of moderate to severe acne vulgaris.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Protocol not approved
  </why_stopped>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-inflammatory lesion counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Absolute change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from Baseline for inflammatory plus non-inflammatory lesions</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline for inflammatory and non-inflammatory lesions</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment of Acne Severity Score (IGA)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose of TSN2898</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid Dose of TSN2898</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose of TSN2898</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Applied once a day</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Topical gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSN2898</intervention_name>
    <description>Applied once a day</description>
    <arm_group_label>Low Dose Active</arm_group_label>
    <other_name>Topical gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSN2898</intervention_name>
    <description>Applied once a day</description>
    <arm_group_label>Mid Dose Active</arm_group_label>
    <other_name>Topical gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSN2898</intervention_name>
    <description>Applied once a day</description>
    <arm_group_label>High Dose Active</arm_group_label>
    <other_name>Topical gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females, 16 to 55 years of age

          -  Must be diagnosed as having moderate or severe acne vulgaris

          -  ≥ 20 inflammatory lesions on the face

          -  ≥ 20 non-inflammatory lesions on the face

          -  ≤ 3 nodule/cyst acne lesions

          -  Medically healthy

          -  Females must be of non-childbearing potential

        Exclusion Criteria:

          -  Systemic therapy with retinoids within six (6) months prior to study start

          -  Topical use of prescription retinoids within four (4) weeks prior to study start

          -  Oral antibiotics within four (4) weeks prior to study start

          -  Topical dapsone, sulfacetamide, benzoyl peroxide, α-hydroxy/glycolic acid and
             retinol/retinaldehyde-containing products, and topical antibiotics, anti-inflammatory
             medications and corticosteroids on the face within two (2) weeks prior to study start

          -  Facial procedures, including lasers, peels, and dermabrasion, within two (2) months
             prior to study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Welgus, MD</last_name>
    <role>Study Director</role>
    <affiliation>Thesan Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thesan Site 4</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thesan Site 3</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thesan Site 6</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thesan Site 5</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thesan Site 2</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thesan Site 1</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Honduras</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne, topical, SCD-1 inhibitor, moderate, severe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

